AQP4阳性NMOSD全 ancestry GWAS 识别遗传风险位点
该研究对2833例个体(含1573例AQP4阳性NMOSD病例和1260例对照)进行全 ancestry GWAS,发现MHC区域和STAT4基因内三个达到全基因组显著性的独立关联。研究提示AQP4阳性NMOSD在遗传上更接近系统性自身免疫病而非多发性硬化,并支持TYK2-STAT4通路作为潜在治疗靶点。
要点
- STAT4内含子变异rs35593987与疾病全基因组显著关联。
核心结论
- AQP4阳性NMOSD遗传上更接近系统性自身免疫病而非多发性硬化。
- 补体C4A相关变异为最大疾病遗传风险因素,可能促进自身抗体产生B细胞发育。
- HLA限制性CD4+ T细胞及TYK2-STAT4通路参与致病,TYK2-STAT4通路为潜在治疗靶点。
研究设计与样本
- 全 ancestry GWAS纳入2833例个体,其中1573例AQP4阳性NMOSD病例和1260例对照。
- 对照包括未患病亲属、健康非亲属和其他自身免疫病患者。
- 样本来自国际NMOSD遗传联盟,覆盖全球36家医院和研究机构。
- 另在1857例欧洲 ancestry 样本(803例病例和1054例对照)中进行第二次GWAS。
主要发现
- 全 ancestry 分析发现三个全基因组显著独立关联:两个位于MHC,一个位于STAT4内含子。
关键数值与推荐
- 病例均符合2015年国际NMOSD诊断共识标准且AQP4-IgG阳性。
临床怎么用
- 遗传证据提示AQP4阳性NMOSD与系统性自身免疫病共享遗传背景,应关注合并干燥综合征和系统性红斑狼疮等。
- TYK2-STAT4通路为潜在治疗靶点,但尚无NMOSD临床干预数据。
- 补体C4A相关变异作为最强风险位点,支持补体参与致病。
局限性
- 原文未报告
- 原文未报告
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the causes of serum aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (AQP4-positive NMOSD) or how its pathophysiology differs from other demyelinating autoimmune diseases, which limits therapeutic and preventative opportunities despite available diagnostic biomarkers. By performing a pan-ancestry genome-wide association study (GWAS), we aimed to deepen our understanding of the genetic architecture of AQP4-positive NMOSD and to explore shared heritability with other autoimmune diseases. METHODS: We performed a pan-ancestry GWAS in 2833 individuals, including 1573 AQP4-positive NMOSD cases and 1260 controls (comprising non-affected relatives, healthy non-relatives, and those with other autoimmune diseases). Samples were collected from the International NMOSD Genetics Consortium, comprising 36 hospitals and research facilities across the world. All individuals with AQP4-positive NMOSD fulfilled the 2015 international consensus diagnostic criteria for NMOSD, including positive AQP4-IgG status. We also performed a second GWAS with only the 1857 samples of European ancestry (803 cases and 1054 controls). We then compared our GWAS findings to those from other autoimmune diseases. FINDINGS: We found three independent associations with AQP4-positive NMOSD that reached genome-wide significance: two within the MHC and a third within an intron of the STAT4 gene. In the pan-ancestry study, we identified a complement C4A-associatied variant, rs1150753 (chr6:32092090:A>G, p=1·61 × 10-29, odds ratio [OR] 2·95, 95% CI 2·44-3·56), rs607929 (chr6:32619221:C>G, p=2·87 × 10-24, OR 1·93, 95% CI 1·70-2·20), and a STAT4-associated variant, rs35593987 (chr2:191051800:AC>A, p=8·49 × 10-14, OR 1·75, 95% CI 1·51-2·03). In Europeans, we identified variants that were either in linkage disequilibrium with or the same as those from the pan-ancestry study: rs1270942 (chr6:31951083:A>G, p=2·52 × 10-28, OR 3·01, 95% CI 2·47-3·66), rs607929 (p=1·12 × 10-20, OR 1·99, 95% CI 1·72-2·30), and rs3821236 (chr2:191038032:G>A, p=1·20 × 10-10, OR 1·74, 95% CI 1·47-2·06). rs1270942 is in linkage disequilibrium with rs1150753 (r2=0·96) as well as two AQP4-positive NMOSD-associated HLA alleles, HLA-DRB1*03:01 (p=2·80 × 10-26, OR 2·79, 95% CI 2·30-3·37) and HLA-B*08:01 (p=1·02 × 10-24, OR 2·68, 95% CI 2·22-3·24). A priori testing of the P1104A variant (rs34536443, chr19:10352442:G>C) within the TYK2 gene, which acts upstream in the STAT4 pathway, found it to be protective (p=0·0008, OR 0·52, 95% CI 0·35-0·76 in the pan-ancestry study). Genetic sharing was observed with several comorbid autoimmune diseases for both the complement C4A-associated and STAT4-associated variants, including Sjögren's syndrome and systemic lupus erythematosus. INTERPRETATION: AQP4-positive NMOSD is more genetically similar to systemic autoimmune diseases than to multiple sclerosis, despite sharing overlapping clinical phenotypes. Specifically, a polymorphism associated with reduced complement C4 was identified as the biggest disease genetic risk factor, which has been shown to facilitate the development of autoantibody-producing B cells. Our findings also support a pathogenic role of HLA-restricted CD4+ T cells, owing to both a genome-wide significant association of HLA-DRB1*03:01 as well as heritable risk within the TYK2-STAT4 signalling pathway. Having already been shown to be a successful target for treating psoriatic arthritis and, potentially, systemic lupus erythematosus, we propose the TYK2-STAT4 pathway as a possible therapeutic target in AQP4-positive NMOSD. FUNDING: The OAK Foundation, The Guthy Jackson Charitable Trust Foundation, and the UK Medical Research Council.
引用
- Attfield KE, Armen AP, Kuttikkatte SB, et al. Identification of genetic risk loci associated with aquaporin 4-positive neuromyelitis optica spectrum disorder: a genome-wide association study. Lancet Neurol. 2026. PMID: 42009010. doi:10.1016/S1474-4422(26)00084-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。